Modified GRF (1–29) / GHRP-6 Blend is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Modified GRF (1–29) and Growth Hormone–Releasing Peptide-6 (GHRP-6). Modified GRF (1–29) is a stabilized analog of growth hormone–releasing hormone (GHRH), while GHRP-6 is a growth hormone secretagogue receptor (GHS-R) agonist originally developed as a hexapeptide. Together, this blend is formulated for laboratory research focused on pulsatile growth hormone release, receptor signaling pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, Modified GRF (1–29) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a short duration of activity. GHRP-6 has been widely researched for its role in ghrelin receptor activation and its influence on growth hormone secretion amplitude and frequency. The combination allows researchers to examine complementary mechanisms involved in growth hormone pulsatility, secretion dynamics, and signaling coordination.
Currently, the Modified GRF (1–29) / GHRP-6 Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic signaling, appetite-related hormone interactions, and circadian growth hormone release patterns. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Modified GRF (1-29), GHRP-6 Blend is developed for laboratory research focused on growth hormone signaling, endocrine pathway communication, and metabolic biomarker responses within controlled experimental environments. By combining a growth hormone–releasing hormone analog with a growth hormone secretagogue, this blend enables researchers to study complementary GH-axis signaling pathways and their influence on pulsatile hormone activity.
Multi-peptide research protocols allow investigators to examine how different signaling inputs interact within the hypothalamic–pituitary axis. When properly structured experimental models are used, these studies can help researchers observe hormone release patterns, endocrine marker fluctuations, and signaling responses that may occur when multiple peptide pathways are activated simultaneously.
Modified GRF (1-29), GHRP-6 Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Modified GRF (1-29) + GHRP-6 |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Modified GRF (1-29) is widely referenced in peptide research as a growth hormone–releasing hormone analog used to investigate pulsatile GH signaling patterns. Researchers studying this compound often focus on how the hypothalamic–pituitary axis regulates hormone release and how endocrine signaling cascades influence downstream metabolic markers.
GHRP-6 is a growth hormone secretagogue studied for its interaction with ghrelin receptor pathways and pituitary response mechanisms. In laboratory models, this peptide is often evaluated for its ability to stimulate hormone release signaling through ghrelin receptor activation.
When these peptides are used together within an experimental framework, investigators may observe how GHRH-related signaling interacts with ghrelin receptor activation. Research protocols often measure hormone pulse amplitude, frequency, and downstream biomarker responses in order to better understand endocrine pathway dynamics.
Researchers interested in examining each compound individually may reference the individual product pages for CJC-1295 (without DAC) (commonly associated with Modified GRF research) and GHRP-6.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
This peptide combination is frequently studied in laboratory models examining pulsatile growth hormone release. Researchers may measure endocrine marker fluctuations across defined sampling intervals to understand how combined pathway activation influences hormone signaling patterns.
Because Modified GRF (1-29) and GHRP-6 interact with different components of the GH-axis signaling system, laboratories may analyze how hypothalamic signals and pituitary responses communicate within endocrine regulatory pathways.
Many GH-axis studies evaluate downstream biomarkers influenced by hormone signaling. Researchers may monitor endocrine marker activity to observe how signaling responses shift when both GHRH and ghrelin receptor pathways are activated.
Experimental designs often include both blended peptide conditions and single-peptide controls. This allows investigators to determine whether observed signaling responses result from individual pathways or the interaction between multiple endocrine signaling inputs.
The Modified GRF (1-29), GHRP-6 Blend should be handled according to standard peptide laboratory procedures emphasizing contamination prevention, proper storage conditions, and detailed protocol documentation. Maintaining stable laboratory environments helps support reproducible experimental outcomes.
Protocol Design Considerations: Growth hormone signaling research is sensitive to circadian rhythm timing, metabolic baseline status, environmental variables, and experimental stress conditions. Standardized sampling windows and carefully controlled laboratory environments are essential for reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports support procurement verification, regulatory documentation, and reproducibility tracking across research studies.
Laboratories sourcing peptides for endocrine signaling research typically prioritize traceable documentation, reliable synthesis standards, and strict quality-control processes. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and manufacturing standards designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
